NewsBur
No Result
View All Result
Friday, January 15, 2021
  • Home
  • Morning News
  • Market News
  • Analyst Actions
  • Trending Stocks
Subscribe
Newsbur
  • Home
  • Morning News
  • Market News
  • Analyst Actions
  • Trending Stocks
No Result
View All Result
Newsbur
No Result
View All Result
Home Market News

Why Marinus Pharmaceuticals Inc [MRNS] Is Set For More Gains Near-Term

by Nick Brown
September 16, 2020
in Market News, Morning News
0
Spring Bank Pharmaceuticals Inc [SBPH] Is Just Getting Started: Here’s Why
0
SHARES
45
VIEWS
Share on FacebookShare on Twitter

Marinus Pharmaceuticals Inc [NASDAQ:MRNS] rallied yesterday and closed the day higher by 51%, The breakout followed news that the company’s treatment for CDKL5 Deficiency Disorder (CDD), a rare genetic epilepsy had met its phase 3 primary  goals. From the trials, the company reported that in 28-days, there was a 32.2% decline in major motor seizure frequency compared to the 4% reduction when using a placebo.

The company also announced that Ganaxolone was well tolerated and that the rate discontinuation was lower than 5% of the subjects that were put under the treatment.

On the basis of these results, the company stated that it would submit an NDA for the treatment to the U.S  F.D.A in the middle of 2021  The company also noted that it would make a Marketing Authorization Application (MAA) for the treatment to the European Medicines Agency within Q3 of 2021.

Commenting on the progress made so far, CEO Scott Braunstein stated that the study had a series of firsts that make it special. One of the firsts that is unique to this project is that it was a double blind placebo. This was used to give clear evidence of the treatment’s efficacy, with strict specificity to CDD.

He added that this was the first phase 3 trial that examined the dosing of ganaxolene 3 times a day in patients. The CEO further stated that he believed the company was a step closer to giving the first treatment for CDD and that the company would continue investing in ganaxolene.

Even more interesting is the CEO’s statement that the company’s successful development of a CDD treatment would create the way for the company to accelerate its studies in other treatments such as those for tuberous sclerosis complex among other rare epilepsies.

From an investor perspective, these developments point to a company that has a growing portfolio of potential revenue generating products. It is also noteworthy that the company announced that it had been awarded a contract by BARDA for the development of IV Ganaxolone.

The company stated that it had entered into a 5-year deal with BARDA (Biomedical Advanced Research and Development Authority) as part of the U.S government’s efforts to treat refractory  status epilepticus (RSE),  a life  threatening ailment that most patients do not respond to treatment. It all points to a company whose fundamentals are getting stronger and the same will reflect in its price action over time.

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc is a biopharma company that develops therapies for rare seizures. It is headquartered in Radnor, Pennsylvania.

Tags: Marinus PharmaceuticalsMRNSMRNS stockNASDAQ:MRNS

Recommended Stories

With a 52-Week Change of 105.93%, Eros International Plc [EROS] is a Better Play Than You Think

August 27, 2020

One Stop Systems Inc. (OSS)’s EPS growth this year surpasses 34.20%. Can investors expect more growth?

July 2, 2020

Biocept Inc. [BIOC] Plummets -6.72%

September 14, 2020

Popular Stories

  • Sorrento Therapeutics Inc. [SRNE] is One of the Best Plays in Healthcare and This Proves It

    0 shares
    Share 0 Tweet 0
  • Heat Biologics Inc. [HTBX] is One of the Best Plays in Healthcare and This Proves It

    0 shares
    Share 0 Tweet 0
  • Heat Biologics Inc. [HTBX] Is Skyrocketing 13.15% on Pure Fundamentals

    0 shares
    Share 0 Tweet 0
  • BlackBerry Limited [BB] is a Top Ten Buy with Quarterly Revenues of 999.00M

    0 shares
    Share 0 Tweet 0
  • Impressive Profit Margins of -5.80% Raise Bull Flags for General Electric Company [GE]

    0 shares
    Share 0 Tweet 0

NewsBur.com

Newsbur.com is an Economic news website, which offers broad information about the Stock markets and Equities. The major emphasis of this platform is to present, the most practical recommendation for public and private capital sharing, both in the form of updates and detailed analysis.

Recent Posts

  • After-Hours Trading Alert: Amgen Inc. [AMGN] is Up 0.85% After the Bell
  • Has Dynatrace Inc. [DT] Completely Outpaced Other Companies in the Technology This Year?
  • Why Applied Materials Inc. [AMAT]’s 1.55% Drop is No Cause for Alarm

Categories

  • Analyst Actions
  • Market News
  • Morning News
  • Trending Stocks
  • Uncategorized

© 2020 Copyright © All Rights Reserved.

No Result
View All Result
  • Home
  • Market News
  • Morning News
  • Analyst Actions
  • Trending Stocks

© 2020 Copyright © All Rights Reserved.